Cerenome (PSTV) Change in Accured Expenses (2010 - 2026)
Plus Therapeutics (PSTV) posted quarterly Change in Accured Expenses of -$13000.0 for Q1 2026, up 99.46% year-over-year from -$6517.5 in Q1 2025, and down 100.2% quarter-over-quarter from $6.5 million in Q4 2025.
Cerenome (PSTV) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Change in Accured Expenses for 17 consecutive years, with -$13000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 99.46% year-over-year to -$13000.0; the TTM figure through Mar 2026 stood at $2.6 million (up 10.18% YoY), while the FY2025 annual figure was $159000.0, down 96.62% from the prior year.
- Change in Accured Expenses retreated to -$13000.0 in Q1 2026 per PSTV's latest filing, from $6.5 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $6.5 million in Q4 2025 and bottomed at -$3.6 million in Q1 2023.
- Historically, Change in Accured Expenses has averaged $448411.8 across 5 years, with a median of $50000.0 in 2023.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 1884.43% — and 2025, when it slumped 5523.26%.
- Plus Therapeutics' Change in Accured Expenses stood at $4.5 million in 2022, then plunged by 91.46% to $384000.0 in 2023, then soared by 779.17% to $3.4 million in 2024, then jumped by 91.56% to $6.5 million in 2025, then tumbled by 100.2% to -$13000.0 in 2026.
- Business Quant data shows PSTV's Change in Accured Expenses at -$13000.0 in Q1 2026, $6.5 million in Q4 2025, and -$1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | 1.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13,000.00 |
| Mar 31, 2026 | -13,000.00 |
| Dec 31, 2025 | 6.47 Mn |
| Dec 31, 2025 | 6.47 Mn |
| Sep 30, 2025 | -1.13 Mn |
| Sep 30, 2025 | -1.13 Mn |
| Jun 30, 2025 | -2.76 Mn |
| Jun 30, 2025 | -2.76 Mn |
| Mar 31, 2025 | -2.42 Mn |
| Mar 31, 2025 | -2.42 Mn |
| Dec 31, 2024 | 3.38 Mn |
| Dec 31, 2024 | 3.38 Mn |
| Sep 30, 2024 | 966,000.00 |
| Sep 30, 2024 | 966,000.00 |
| Jun 30, 2024 | 403,000.00 |
| Jun 30, 2024 | 403,000.00 |
| Mar 31, 2024 | -43,000.00 |
| Mar 31, 2024 | -43,000.00 |
| Dec 31, 2023 | 384,000.00 |
| Dec 31, 2023 | 384,000.00 |